Introducing 

Prezi AI.

Your new presentation assistant.

Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.

Loading…
Transcript

CEACAM6

CEACAM6_ Diseases

Step 3: Background Literature Profiling

CEACAM6_ Cell Types

CEACAM6_ Diseases_Biomarker

N Articles

> 50

> 20

> 10

Cancer

> 5

> 1

Colorectal Cancer

Pancreatic Cancer

Lung Cancer

Breast Cancer

Pregnancy

Leukemia

Myeloma

Cholangiocarcinoma

Inflammatory Bowel Disease

Thyroid

Cancer

Head and Neck Cancer

Ovarian Cancer

CEACAM6_ Diseases_

Laryngeal Cancer

Osteosarcoma

Cystic Fibrosis

Gastro

intestinal Cancer

Asthma

CEACAM6_Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Cancer [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Cancer+%5Btiab%5D%29&sort=pubdate

Results

202 Articles

(Mar 24, 2022)

Highlights

_Colorectal Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Colorectal Cancer" [tiab] OR "Colon Cancer" [tiab] OR "Colon Carcinoma" [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Colorectal+Cancer%22+%5Btiab%5D+OR+%22Colon+Cancer%22++%5Btiab%5D++OR+%22Colon+Carcinoma%22+%5Btiab%5D%29&sort=pubdate

Results

69 Articles

(Mar 24, 2022)

Highlights

CEACAM6_ Diseases_

_Biomarker

CEACAM6_Pancreatic Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Pancreatic cancer" [tiab] OR "Pancreatic carcinoma" [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Pancreatic+cancer%22+%5Btiab%5D+OR+%22Pancreatic+carcinoma%22+%5Btiab%5D%29&sort=pubdate

Results

31 Articles

(Mar 24, 2022)

Highlights

CEACAM6_Lung Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Lung Cancer" [tiab] OR "Lung Adenocarcinoma" [tiab] OR "Lung Carcinoma" [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Lung+Cancer%22+%5Btiab%5D+OR+%22Lung+Adenocarcinoma%22+%5Btiab%5D+OR+%22Lung+Carcinoma%22+%5Btiab%5D%29&sort=pubdate

Results

35 Articles

(Mar 24, 2022)

Highlights

CEACAM6_Leukemia

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Leukemia [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Leukemia+%5Btiab%5D%29&sort=pubdate

Results

35 Articles

(Mar 24, 2022)

Highlights

CEACAM6_IBD

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Inflammatory bowel disease" [tiab] OR "Crohn's Disease" [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Inflammatory+bowel+disease%22+%5Btiab%5D+OR+%22Crohn%27s+Disease%22+%5Btiab%5D%29&sort=pubdate

Results

30 Articles

(Mar 24, 2022)

Highlights

CEACAM6_Breast Cancer

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Breast Cancer" [tiab] OR "Breast Carcinoma" [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Breast+Cancer%22+%5Btiab%5D+OR+%22Breast+Carcinoma%22+%5Btiab%5D%29&sort=pubdate

Results

28 Articles

(Mar 24, 2022)

Highlights

CEACAM6_Ovarian Cancer

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Ovarian Cancer" [tiab] OR "Ovarian Carcinoma" [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Ovarian+Cancer%22+%5Btiab%5D+OR+%22Ovarian+Carcinoma%22+%5Btiab%5D%29&sort=pubdate

Results

5 Articles

(Mar25, 2022)

Highlights

CEACAM6_GI Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Gastric Cancer" [tiab] OR "Gastric Carcinoma" [tiab], "Gastric Adenocarcinoma" [tiab] OR "Gastrointestinal Cancer" [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Gastric+Cancer%22+%5Btiab%5D+OR+%22Gastric+Carcinoma%22+%5Btiab%5D%2C+%22Gastric+Adenocarcinoma%22+%5Btiab%5D+OR+%22Gastrointestinal+Cancer%22+%5Btiab%5D%29&sort=pubdate

Results

2 Articles

(Mar25, 2022)

Highlights

CEACAM6_Thyroid Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Thyroid Carcinoma" [tiab] OR "Thyroid Cancer" [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Thyroid+Carcinoma%22+%5Btiab%5D+OR+%22Thyroid+Cancer%22+%5Btiab%5D%29&sort=pubdate

Results

3 Articles

(Mar25, 2022)

Highlights

CEACAM6_Cystic Fibrosis

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Cystic fibrosis" [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/20047061/

Query Link

Results

1 Article

(Mar25, 2022)

Highlights

CEACAM6_Head & Neck Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Head and Neck cancer" [tiab] OR "Head and Neck Carcinoma" [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/23021083/

Query Link

Results

1 Article

(Mar25, 2022)

Highlights

CEACAM6_Osteosarcoma

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Osteosarcoma [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Osteosarcoma+%5Btiab%5D%29&sort=pubdate

Query Link

Results

2 Articles

(Mar25, 2022)

Highlights

CEACAM6_Asthma

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Asthma [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Asthma+%5Btiab%5D%29&sort=pubdate

Query Link

Results

4 Articles

(Mar25, 2022)

https://pubmed.ncbi.nlm.nih.gov/28275137/

- In lungs of patients with Asthma expressed in both airway epithelial cells and in neutrophils.

- The abundance of neutrophils is not changed in Asthma patients, but the proportion of neutrophils expressing CEACAM6 is increased.

Highlights

CEACAM6_Laryngeal Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Laryngeal cancer" [tiab] OR "Laryngeal carcinoma" [tiab] OR "Laryngeal squamous cell carcinoma" [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/30094098/

Query Link

Results

1 Article

(Mar25, 2022)

Highlights

CEACAM6_Pregnancy

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Pregnancy [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Pregnancy+%5Btiab%5D%29&sort=pubdate

Results

14 Articles

(Mar 24, 2022)

Highlights

CEACAM6_Myeloma

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("myeloma" [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22myeloma%22+%5Btiab%5D%29&sort=pubdate

Results

9 Articles

(Mar 24, 2022)

Highlights

CEACAM6_Cholangiocarcinoma

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Cholangiocarcinoma [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Cholangiocarcinoma+%5Btiab%5D%29&sort=pubdate

Results

7 Articles

(Mar 24, 2022)

Highlights

N Articles

> 50

> 20

> 10

Colorectal Cancer

> 5

> 1

Breast Cancer

Pancreatic Cancer

Leukemia

Lung Cancer

CEACAM6_ Diseases_Biomarker

Association with poor survivial/prognosis

Marker for early detection in blood

As a cancer stem cell marker

CEACAM6_ Diseases_Biomarker

_Colorectal Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Colorectal Cancer" [tiab] OR "Colon Cancer" [tiab] OR "Colon Carcinoma" [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Colorectal+Cancer%22+%5Btiab%5D+OR+%22Colon+Cancer%22+%5Btiab%5D+OR+%22Colon+Carcinoma%22+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D%29&sort=date

Query Link

Results

15 Articles

(Sept 05, 2022)

26993598

Rodia et al.

Oncotarget

2016

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058681/

29352642

Rodia et al.

Clin Colorectal Cancer

2018

27042567

Nataraj et al.

J Clin Diagn Res.

2016

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800633/

22975528

Kim et al.

Clinica Chim Acta.

2013

14512395

Jantscheff et al.

J. Clin Oncol

2003

Association with poor survivial/prognosis

Marker for differentiation of malignant vs benign tumors

CEACAM6_ Diseases_Biomarker

_Pancreatic Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Pancreatic cancer" [tiab] OR "Pancreatic carcinoma" [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Pancreatic+cancer%22+%5Btiab%5D+OR+%22Pancreatic+carcinoma%22+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D%29&sort=date

Query Link

Results

18 Articles

(Sept 05, 2022)

34321959

Liu et al.

Pathology & Oncology Res.

2021

https://www.por-journal.com/articles/10.3389/pore.2021.1609868/full

23806607

Farina et al.

Biochimica et Biophysica Acta

2014

34207784

Kurlinkus et al.

Life

2021

https://www.mdpi.com/2075-1729/11/6/542/htm

25409014

Gebauer et al.

PlosOne

2014

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113023

15729073

Duxbury et al.

Ann Surg

2005

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356989/

23857344

Chen et al.

Int J Oncol

2013

https://www.spandidos-publications.com/ijo/43/3/877

Associated with poor survivial/prognosis

CEACAM6_ Diseases_Biomarker

_Lung Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Lung Cancer" [tiab] OR "Lung Adenocarcinoma" [tiab] OR "Lung Carcinoma" [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Lung+Cancer%22+%5Btiab%5D+OR+%22Lung+Adenocarcinoma%22+%5Btiab%5D+OR+%22Lung+Carcinoma%22+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D%29&sort=date

Query Link

Results

11 Articles

(Sept 05, 2022)

35358791

Kim et al.

Translation Oncology

2022

https://www.sciencedirect.com/science/article/pii/S193652332200064X?via%3Dihub

33664813

Cao et al.

Oncol Lett

2021

https://www.spandidos-publications.com/10.3892/ol.2021.12510

28731711

Codreanu et al.

J Proteome Res

2019

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339813/

This study evaluated the diagnostic ability of CD66c in lung adenocarcinoma-associ- ated malignant pleural effusions (LA-MPEs) and compared it with other known tumour markers.

25551300

Son et al.

Pathology

2015

25427744

Lee et al.

Virchows Arch

2015

https://link.springer.com/article/10.1007/s00428-014-1688-1

CEACAM6_ Diseases_Biomarker

_Leukemia

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Leukemia [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab])

Query

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Leukemia+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D%29&sort=date

Query Link

Results

16 Articles

(Sept 05, 2022)

20666852

Guillaume et al.

Int J Lab Hematol

2011

15826304

Kalina et al.

BMC Cancer

2005

https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-5-38.pdf

As a cancer stem cell marker

Early detection

Associated with poor survivial/prognosis

CEACAM6_ Diseases_Biomarker

_Breast Cancer

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Breast Cancer" [tiab] OR "Breast Carcinoma" [tiab] OR "Breast tumor" [tiab] OR "breast tumors" [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab] OR sensitivity [tiab] OR specificity [tiab] OR "positive predictive value" [tiab] OR "negative predictive value" [tiab] OR "odds ratio" [tiab] OR "fold change" [tiab] OR "association" [tiab] OR "associated" [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Breast+Cancer%22+%5Btiab%5D+OR+%22Breast+Carcinoma%22+%5Btiab%5D+OR+%22Breast+tumor%22+%5Btiab%5D+OR+%22breast+tumors%22+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D+OR+sensitivity+%5Btiab%5D+OR+specificity+%5Btiab%5D+OR+%22positive+predictive+value%22+%5Btiab%5D+OR+%22negative+predictive+value%22+%5Btiab%5D+OR+%22odds+ratio%22+%5Btiab%5D+OR+%22fold+change%22+%5Btiab%5D+OR+%22association%22+%5Btiab%5D+OR+%22associated%22+%5Btiab%5D%29&sort=date

Results

20 Articles

(Sept 05, 2022)

32235022

Koh, et al.

Mol Cells

2020

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191048/

24186057

Tsang, et al.

Breast Cancer Res Treat.

2013

18223215

Maraqa, et al.

Clin Cancer Res.

2008

https://aacrjournals.org/clincancerres/article/14/2/405/196147/Carcinoembryonic-Antigen-Cell-Adhesion-Molecule-6

34447411

Huskey, et al.

Front. in Genetics

2021

Overall, gene-based aggregation analyses revealed that rare PTVs in CEACAM6, CEACAM7, and CEACAM8 are associated with European American breast cancer risk, and rare PTVs in CEACAM7 are associated with breast cancer risk in African Americans (Table 5).

EA = European American

AA = African American

PTV = protein truncating variant

https://www.frontiersin.org/articles/10.3389/fgene.2021.702889/full

16899629

Poola

Clin Cancer Res.

2006

https://aacrjournals.org/clincancerres/article/12/15/4773/188827/Expression-of-Carcinoembryonic-Antigen-Cell

N Articles

> 50

> 20

> 10

> 5

Granulocytes

> 1

T-cells

Intestinal Epithelial Cells

Neutrophils

Sertoli Cells

Pancreatic Cancer Cells

Breast Cancer Cells

Lymphoblastic Leukemia Cells

CEACAM6_ Cell Types_

Airway Epithelial

Cells

Cancer Stem Cells

CEACAM6_Granulocytes

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("granulocytes" [tiab] OR "granulocyte" [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22granulocytes%22+%5Btiab%5D+OR+%22granulocyte%22+%5Btiab%5D%29&sort=date&size=200&show_snippets=off

Results

66 Articles

(Dec 05, 2021)

Results Link

https://pubmed.ncbi.nlm.nih.gov/?term=34467524+27626616+23941132+23630956+22768164+19334050+18056392+17909799+17517873+15541289+15488142+14707113+12379336+11994468+11847104+10666389+10475238+9862166+9714468+9427723+8890209+8664114+7594554+7591230+7735161+8018919+8119777+7736546+8104998+7690348+8099907+7683969+8508798+1458480+1431566+1640165+1323111+1592535+1370882+1370907+2050678+1849127+1824544+1778210+2174725+2208113+1701159+2178978+2306228+1690879+2154215+2408131+2261596+2475724+2474516+3211435+3211433+3128509+3320743+3568003+2420267+3882113+6724739+6713409+6987861+92357&show_snippets=off&sort=date&size=200

Evaluation of the CEACAM6 literature associated with Granulocytes indicates that its expression on this cell type is well-documented. It is however not restricted to Granulocytes as it is also expressed in normal and malignant tissues. One article also indicates that its expression in normal bone marrow is restricted to myeloid cells and expressed at particularly high levels in promyelocytes [9714468]

Highlights

https://pubmed.ncbi.nlm.nih.gov/3320743/

https://pubmed.ncbi.nlm.nih.gov/9714468/

CEACAM6 = CD66c

Early description of CECAM6 and CEACAM8 in granulocytes (presumably)

CEACAM6_Neutrophils

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("neutrophil" [tiab] OR "neutrophils" [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22neutrophil%22+%5Btiab%5D+OR+%22neutrophils%22+%5Btiab%5D%29&show_snippets=off&sort=date&size=200

Results

43 Articles

(Dec 30, 2021)

https://pubmed.ncbi.nlm.nih.gov/?term=34847408+34707398+34639156+34467524+34217339+32019805+29760215+29518953+28292985+28275137+23630956+22064717+21470677+20560140+19077207+18552205+17561254+15541289+12005421+11590190+11333142+10754323+10496313+9427723+9332316+9218600+8977287+8699114+8776764+8645267+8542935+7594554+8543346+7897228+8104998+7689841+8099907+1359882+1431566+1640165+1378450+1712645+1694660&show_snippets=off&sort=date&size=200

Results Link

https://pubmed.ncbi.nlm.nih.gov/8543346/

https://pubmed.ncbi.nlm.nih.gov/8699114/

https://pubmed.ncbi.nlm.nih.gov/11590190/

Highlights

CEACAM6_Intestinal Epithelial Cells

Query

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("intestinal epithelial cell*" [tiab])

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Bti%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Bti%5D+OR+CD66c+%5Bti%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22granulocytes%22+%5Btiab%5D+OR+%22granulocyte%22+%5Btiab%5D%29&show_snippets=off&sort=date&size=200

Results

26 Articles

(Dec 05-, 2021)

https://pubmed.ncbi.nlm.nih.gov/?term=23941132+18056392+17909799+15541289+15488142+12379336+10666389+10475238+9862166+9714468+9427723+8890209+8664114+7591230+7735161+8018919+8119777+7736546+8104998+7690348+8099907+7683969+8508798+1458480+1431566+1640165+1323111+1592535+1370882+1370907+2050678+1849127+1824544+1778210+2174725+2208113+1701159+2178978+2306228+1690879+2154215+2408131+2261596+2475724+2474516+3211435+3211433+3128509+3320743+3568003+2420267+3882113+6724739+6713409+6987861+92357&show_snippets=off&sort=date&size=200

Results Link

CEACAM6 is recruited to the surface of mucosa cells, including intestinal epithelial cells, by pathogen and possesses immunomodulatory properties (promoting the epithelial cell immune response to pathogens) [28292985]

https://pubmed.ncbi.nlm.nih.gov/28292985/

https://pubmed.ncbi.nlm.nih.gov/24898815/

https://pubmed.ncbi.nlm.nih.gov/25706391/

Highlights

https://pubmed.ncbi.nlm.nih.gov/24326999/

CEACAM6_T-cells

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (T-cell [tiab] OR T-cells [tiab] OR T-lymphocytes [tiab] OR T-lymphocyte [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28T-cell+%5Btiab%5D+OR+T-cells+%5Btiab%5D+OR+T-lymphocytes+%5Btiab%5D+OR+T-lymphocyte+%5Btiab%5D%29&show_snippets=off&sort=date&size=200

Results

27 Articles

(Dec 30, 2021)

https://pubmed.ncbi.nlm.nih.gov/?term=34707398+34467524+33838601+33674603+32849600+32368831+31797958+30546940+28521477+28292985+27284373+26271985+25872647+24040308+23603913+19637360+20063526+17909799+17561254+17057200+16485257+11994468+9714468+9218600+7808000+2185585+6837309&sort=date&size=200&show_snippets=off

Results Link

https://pubmed.ncbi.nlm.nih.gov/27284373/

https://pubmed.ncbi.nlm.nih.gov/23603913/

Highlights

###_---

---

Query

----

Query Link

Results

- Articles

(Nov --, 2020)

---

Results Link

Highlights

###_---

---

Query

----

Query Link

Results

- Articles

(Nov --, 2020)

---

Results Link

Highlights

###_---

---

Query

----

Query Link

Results

- Articles

(Nov --, 2020)

---

Results Link

Highlights

###_---

---

Query

----

Query Link

Results

- Articles

(Nov --, 2020)

---

Results Link

Highlights

###_---

---

Query

----

Query Link

Results

- Articles

(Nov --, 2020)

---

Results Link

Highlights

###_---

---

Query

---

Query Link

Results

-- Articles

(Nov --, 2020)

---

Results Link

Highlights

CEACAM6/Blood Tx

GSE100150

Step 5: Blood Tx Data Profiling

CEACAM6/Blood Stim

GSE30101

CEACAM6/LeukocytesGSE60424

COPD

Influenza

JDM

RSV

Transplant

> 10

> 5

MS

HIV

Expression

(FC over control)

> 2

CEACAM6

Melanoma

Pregnancy

> 1.5

GSE100150

<-1.5

TB

SoJIA

<-2

Expression

(FC over control)

<-5

B-cell deficiency

<-10

Sepsis

Kawasaki

S. aureus

SLE

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Influenza infection and healthy controls. The fold change between the two groups is 5.74, p=0.018 (two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/Nd

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Respiratory Syncytial Virus (RSV) and uninfected controls. The fold change between the two groups is 17.2, p<0.001 (two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/NV

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including pregnant women and non pregnant controls. Fold change between the two groups is 2.00, p=0.0069 (two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/Ne

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Tuberculosis (TB) and uninfected controls. The fold change between the two groups is 1.3, p=0.5 (two-tailed homoscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/NX

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with sepsis and uninfected controls. Fold change between the two groups is 4.96, p<0.01 (two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/Nb

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with acute Staphylococcus aureus (S. aureus) infection and uninfected controls. Fold change between the two groups is 12.3, p<0.0001 (two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/Na

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Systemic Lupus Erythematosus (SLE) and healthy controls. Fold change between the two groups is 2.24 p=0.14 (two-tailed homoscedastic t-test). NS= not significant.

http://cd2k.gxbsidra.org/dm3/miniURL/view/NZ

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Kawasaki Disease and healthy controls. The fold change in Kawasaki patients over healthy controls is 6.08, p=0.010 (two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/NS

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Systemic onset Juvenile Idiopathic Arthritis and controls. Fold change between the two groups is 5.14, p=0.018 (two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/NY

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with multiple sclerosis and controls. Fold change between the two groups is 1.09, p=0.76 (NS, two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/NO

"Subjects enrolled in the MS cohort had an established diagnosis of relapsing-remitting MS, separately confirmed by an experienced MS neurologist (JTP), exhibited no other health conditions, and had received no treatment(s) for MS, including corticosteroids, for at least 3 months prior to blood collection" (Altman et al. 2022: https://www.nature.com/articles/s41467-021-24584-w)

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Juvenile Dermatomyositis and healthy controls. The fold change between the two groups is 1.70, p=0.57 (two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/NL

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including liver transpant recipients under mainenance immunosuppressive therapy and healthy controls. The fold change between the two groups is 3.46, p<0.001 (two-tailed heteroscedastic t-test).

Enrollment criteria included age 17–65 years, having received a liver transplant under maintenance immunosuppression therapy. Subjects in this cohort had not received an acute or chronic rejection diagnosis at the time of sampling [https://www.nature.com/articles/s41467-021-24584-w]

http://cd2k.gxbsidra.org/dm3/miniURL/view/Nc

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Melanoma and healthy controls. Fold change between the two groups is 3.7, p=0.064 (NS, two-tailed heteroscedastic t-test).

http://cd2k.gxbsidra.org/dm3/miniURL/view/NM

Enrollment criteria included age 21–75 years, stage M1a, M1b, M1c biopsy proven metastatic melanoma patients with measurable metastatic lesions by physical examination or scans, acceptable CBC and blood chemistry results, adequate hepatic and renal function, and no active CNS metastatic disease [https://www.nature.com/articles/s41467-021-24584-w]

NS

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy controls. The fold change between the two groups is 1.4, p=0.32 (two-tailed homoscedastic t-test). NS= not significant.

Enrollment criteria included age over 40 years, no history of concurrent lung cancer, chest surgery, or chronic lung diseases other than COPD (e.g., sarcoidosis, fibrosis, etc.). Participants had no history of allergies or asthma and at the time of initial recruitment had not received oral or systemic corticosteroids during the previous 6 weeks; volunteers were enrolled from three clinics within the Texas Medical Center in Houston (TX, USA) [https://www.nature.com/articles/s41467-021-24584-w]

http://cd2k.gxbsidra.org/dm3/miniURL/view/NI

NS

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with B-cell deficiency and healthy controls. Fold change between the two groups is 1.97, p=0.3 (two-tailed heteroscedastic t-test). NS= not significant.

http://cd2k.gxbsidra.org/dm3/miniURL/view/NJ

This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with HIV infection and healthy controls. The fold change between the two groups is 2.14, p=0.026 (two-tailed heteroscedastic t-test).

Blood samples were obtained from adult patients diagnosed with HIV infection. At enrollment patients were verified as acute Fiebig stages 4–6 (plasma RNA + , third-generation EIA+, Western blot indeterminant or + ) [https://www.nature.com/articles/s41467-021-24584-w]

http://cd2k.gxbsidra.org/dm3/miniURL/view/NK

This violin plot shows fold change in abundance of CEACAM6 RNA measured by RNA sequencing in the blood of human subjects across different disease cohorts, compared to their respective control subjects.

Reference: Altman, Rinchai et al. Nat Comms 2021

Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100150;

Plot: https://chart-studio.plotly.com/create/?fid=dchaussabel%3A132

Interactive version with values expressed as counts: http://cd2k.gxbsidra.org/dm3/miniURL/view/NH

IFNb

TNF

IFNa2b

E-LPS

IFNg

> 10

IL18

> 5

HK E. Coli

Zymosan

HKAL

Expression

(FC over control)

CEACAM6

> 2

> 1.5

GSE30101

<-1.5

PolyIC

HKLP

R837

Flagellin

<-2

Expression

(FC over control)

<-5

RSV

<-10

HKSA

PAM3

Influenza

CPG

Levels of CEACAM6 transcript abundance in blood exposed to immune stimuli in vitro. The box plot represents transcript abundance levels for the CEACAM6 gene in blood samples obtained from four healthy donors, cultivated for 6 hours at 37°C in the presence of pathogens, as well as pathogen-derived and host-derived immune stimuli (HKAL = heat-killed Acholeplasma laidlawii, HKLP = heat-killed Legionella pneumophila, HKSA = heat-killed Staphylococcus aureus, Flu = live influenza A virus, RSV = live respiratory syncytial virus).

For details, see original work by Obermoser et al., Immunity, 2013

GEO deposition: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30101

Plot: https://plotly.com/~dchaussabel/173/

CEACAM6_Leukocytes_

GSE60424

> 30

> 10

Expression

(FC over control)

> 5

CEACAM6GSE60424

> 1.5

<-1.5

<-5

Expression

(FC over control)

<-10

<-30

This box plot shows levels of abundance of CEACAM6 RNA measured by RNA sequencing in neutrophils, monocytes, B-cells, CD4 T-cells, CD8 T-cells and NK cells purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls. Values are normalized to the median calculated across all conditions.

Reference: Linsley et al. https://pubmed.ncbi.nlm.nih.gov/25314013/

Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60424;

Plot: https://chart-studio.plotly.com/create/?fid=dchaussabel%3A132

Interactive version with values expressed as counts: http://cd2k.gxbsidra.org/dm3/miniURL/view/NH

> 20

> 10

Expression

(FC over median)

> 5

> 2

> 50

Literature profiles

> 20

Literature

(N articles)

> 5

> 0

The PubMed query for the gene of interest is run again title and abstract text ([tw]) AND includes terms to restrict the query to literature relevant to a particular cell type:

ISG15 [tw] OR "ISG15 Ubiquitin Like Modifier" [tw] OR "Interferon-stimulated gene 15" [tw] OR "IFN-induced 15-kDa protein" [tw] OR IFI-15K [tw] OR "Ubiquitin Cross-Reactive Protein" [tw] OR "Ubiquitin-Like Protein ISG15" [tw] OR (HUCRP [tw] AND "Cross-Reactive Protein" [tw]) OR G1P2 [tw] OR IP17 [tw] OR (UCRP [tw] AND "Cross-Reactive Protein" [tw]) OR "Interferon-Induced 17-KDa/15-KDa Protein" [tw] OR "Interferon-Stimulated Protein, 15 Kda" [tw] OR "Interferon-Induced 17 Kda Protein" [tw] OR IFI15 [tw] OR IMD38 [tw] NOT review [pt] AND (monocyte OR monocytes)

Expression profiles

This box plot shows levels of abundance of ISG15 RNA measured by RNAseq in neutrophils, monocytes, B-cells, CD4 T-cells, CD8 T-cells and NK cells purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls.

Box plots can be generated either in Excel or using Plotly (online tool)

https://chart-studio.plotly.com/create/

Generating box plots

https://plotly.com/~dchaussabel/122/

https://docs.google.com/presentation/d/18G45CIp29PqwUYGaAmrb_m-PWLXsjuaPVLqGXD8xY0s/edit?usp=sharing

Generating Figure legends

This box plot shows levels of abundance of ISG15 RNA measured by RNAseq in neutrophils purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls.

This box plot shows levels of abundance of ISG15 RNA measured by RNAseq in neutrophils, monocytes, B-cells, CD4 T-cells, CD8 T-cells and NK cells purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls.

Download button

Accessing data

http://cd2k.gxbsidra.org/dm3/miniURL/view/Mk

1) Access interactive figure

CD8

T-cells

B-Cells

NK Cells

Neutrophils

This box plot shows levels of abundance of CEACAM6 RNA measured by RNA sequencing in neutrophils, monocytes, B-cells, CD4 T-cells, CD8 T-cells and NK cells purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls. Values are normalized to the median calculated across all conditions.

Reference: Linsley et al. https://pubmed.ncbi.nlm.nih.gov/25314013/

Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60424;

Plot: https://chart-studio.plotly.com/create/?fid=dchaussabel%3A132

Interactive version with values expressed as counts: http://cd2k.gxbsidra.org/dm3/miniURL/view/NH

CD4

T-cells

Monocytes

?

+

Food-induced Anaphylaxis

> 20

Parkinson's Disease

> 5

Expression

(FC over control)

> 2

> 1.5

<-1.5

<-2

Expression

(FC over control)

<-5

<-20

?

-

Step 4: Blood Tx Literature

Profiling

N Articles

> 5

> 2

1

CEACAM6_ Blood TX_

Infante et al.

Neurobiology of Aging

2015

Topic

https://www.sciencedirect.com/science/article/pii/S0197458014007052

Munoz-Cano et al

JACI

2015

Topic

https://europepmc.org/article/pmc/pmc4715677

Idiopathic Pulmonary Fibrosis

22761659

Yang et al.

Plos ONE

2012

Table 5. Differentially-expressed genes between mild and severe cases of IPF.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0037708

Early-onset Preeclampsia

Chaiworapongsa, et al.

J of Perinatal Med

2013

https://www.degruyter.com/document/doi/10.1515/jpm-2013-0082/html

Colorectal cancer

26993598

Rodia, et al.

Oncotarget

2016

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058681/

29352642

Rodia et al.

Clin Colorectal Cancer

2018

COVID-19

35844004

Jackson, et al.

Sci Rep

2022

https://www.nature.com/articles/s41598-022-15547-2

https://www.nature.com/articles/s41591-020-0944-y

29352642

Prokop et al.

Front Immunol

2022

https://www.frontiersin.org/articles/10.3389/fimmu.2021.694243/full

Lung

cancer

34288383

Zhang, et al.

J Cell and Molec Med

2021

https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.16773

Female SoJIA patients

Prada-Medina, et al.

JLB

2020

https://jlb.onlinelibrary.wiley.com/doi/full/10.1002/JLB.6MA0720-015RR?casa_token=g31iFpT5XSYAAAAA%3AChPeV--nP42JTPZJLgi2JMRYuJGrY-wbHHqLzRsCbh-gVPc6Orrdb-tRaNfGQRt9IDEH0WWKBgOmgIU

Late-onset Preeclampsia

Chaiworapongsa, et al.

J of Perinatal Med

2013

https://www.degruyter.com/document/doi/10.1515/jpm-2013-0082/html

CEACAM6_Entrez Gene

CEACAM6_OMIM

CEACAM6_UniProt

Step 2: Gathering Background Information

CEACAM6_Wikipedia

CEACAM6_

Intros

CEACAM6_Entrez Gene

Summary

This gene encodes a protein that belongs to the carcinoembryonic antigen (CEA) family whose members are glycosyl phosphatidyl inositol (GPI) anchored cell surface glycoproteins. Members of this family play a role in cell adhesion and are widely used as tumor markers in serum immunoassay determinations of carcinoma. This gene affects the sensitivity of tumor cells to adenovirus infection. The protein encoded by this gene acts as a receptor for adherent-invasive E. coli adhesion to the surface of ileal epithelial cells in patients with Crohn's disease. This gene is clustered with genes and pseudogenes of the cell adhesion molecules subgroup of the CEA family on chromosome 19. [provided by RefSeq, Apr 2014]

https://www.ncbi.nlm.nih.gov/gene/4680

CEACAM6_UniProt

Cell surface glycoprotein that plays a role in cell adhesion and tumor progression (PubMed:2803308, PubMed:2022629, PubMed:1378450, PubMed:8776764, PubMed:11590190, PubMed:10910050, PubMed:14724575, PubMed:16204051). Intercellular adhesion occurs in a calcium- and fibronectin-independent manner (PubMed:2022629, PubMed:16204051). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8 (PubMed:2803308, PubMed:2022629, PubMed:8776764, PubMed:11590190, PubMed:16204051). Heterophilic interaction with CEACAM8 occurs in activated neutrophils (PubMed:8776764). Plays a role in neutrophil adhesion to cytokine-activated endothelial cells (PubMed:1378450). Plays a role as an oncogene by promoting tumor progression; positively regulates cell migration, cell adhesion to endothelial cells and cell invasion (PubMed:16204051). Also involved in the metastatic cascade process by inducing gain resistance to anoikis of pancreatic adenocarcinoma and colorectal carcinoma cells (PubMed:10910050, PubMed:14724575)

https://www.uniprot.org/uniprot/P40199

https://journals.sagepub.com/doi/10.1177/17588359211072621

Burgos

Ther. Adv in Medical Oncology

2022

"CEACAM6 is a member of the carcinoembryonic antigen molecules, widely distributed in epithelial and myeloid cells.12 It acts as an intercellular cell adhesion molecule to maintain tissue architecture through interactions with other CEACAM proteins.13 It has been described as a modulator of cancer progression due to its

effects on differentiation and cell growth, resistance to anoikis, treatment resistance, invasiveness and metastasis.14 Indeed, CEACAM6 is upregulated preferentially at the apical/luminal membranes of many tumors.12 This effect was first observed in leukemia15 and subsequently in colorectal,16 pancreatic,17 gastric,18 lung,19 and many others.20–23 Recently, CEACAM6 has been suggested as a target for different cancer immunotherapies given the fact that its membrane expression is highly specific of tumor cells.11 In models of non-small cell lung cancer, different antibodies against CEACAM6 block cell viability, invasion, and migration through inhibition of Src/FAK phosphorylation.24 In models of pancreatic adenocarcinoma, the use of monoclonal antibodies (mAb) against this protein sensitizes cells to cytotoxicity using secondary antibodies.25 A different immunotherapy strategy is the development of humanized single-chain antibody variable fragments (scFv) based on CEACAM6,26 or specific CEACAM6-single domain antibodies (sdAB)

that have demonstrated to inhibit cell growth.27 CEACAM6 has also been used to create antibody–drug conjugates (ADC), using a tubulin

inhibitor as a payload, showing preclinical efficacy in pancreatic cancer.28"

https://www.tandfonline.com/doi/epub/10.1080/2162402X.2021.2008110?needAccess=true

Pinkert

Oncoimmunology

2022

CEACAM6_Wikipedia

https://en.wikipedia.org/wiki/CEACAM6

CEACAM6_OMIM

▼ Description

Carcinoembryonic antigen (CEA; 114890) is one of the most widely used tumor markers in serum immunoassay determinations of carcinoma. An apparent lack of absolute cancer specificity for CEA probably results in part from the presence in normal and neoplastic tissues of antigens that share antigenic determinants with the 180-kD form of CEA (Barnett et al., 1988). For background information on the CEA family of genes, see CEACAM1 (109770).

▼ Cloning and Expression

Barnett et al. (1988) presented sequences of a 'normal crossreacting antigen' (NCA) and showed that CEA and NCA, although closely related in sequence, are structurally and probably functionally distinct.

Using immunohistochemical analysis, Scholzel et al. (2000) showed that human CEACAM6 was expressed in granulocytes and epithelial cells in various organs. In squamous epithelial cells, CEACAM6 displayed nonpolarized cell surface localization and cytoplasmic localization, but in simple epithelia, CEACAM6 was present on the apical surface. CEACAM6 exhibited apical expression throughout colon development and was found in the upper half of developing crypts. CEACAM6 expression correlated with expression of CD95 (FAS; 134637) and with apoptosis at the table region of normal colon, but CEACAM6 was absent from highly proliferating cells at the base of colonic crypts.

▼ Mapping

By in situ hybridization, Willcocks et al. (1989) mapped NCA to 19q13 in the same region as CEA. The localization was supported by studies with a somatic cell hybrid cell line. By a combination of Southern blot analysis and in situ hybridization, Inazawa et al. (1989) localized the gene to 19q13.2.

▼ Gene Function

In 15 patients with Crohn disease (CD; see 266600) and 9 controls, Barnich et al. (2007) found that adherent-invasive E. coli (AIEC) adhesion was dependent on type 1 pili expression on the bacterial surface and on CEACAM6 expression on the apical surface of ileal epithelial cells. CEACAM6 acted as a receptor for AIEC adhesion and was upregulated in the ileal mucosa of CD patients compared to colonic mucosa or to controls. In vitro studies showed increased CEACAM6 expression in cultured intestinal epithelial cells after IFN-gamma (147570) or TNF-alpha (191160) stimulation and after infection with AIEC.

By desensitizing neutrophils to stimulation by various combinations of anti-CD66 antibodies, Skubitz and Skubitz (2008) showed that the 4 neutrophil CEACAMs, including CEACAM6, had significant independent signaling functions. However, the results suggested that the CEACAMs may also act in combination, with CEACAM1 having a unique role.

By screening a panel of pancreatic cancer cell lines for sensitivity to adenovirus, followed by differential gene expression analysis between sensitive and insensitive cells, Wang et al. (2009) found that CEACAM6 expression correlated with the sensitivity of tumor cells to the virus. CEACAM6 blocked adenovirus trafficking to the nucleus through the SRC (190090) pathway, interfering with cancer cell cytoskeleton and reducing adenoviral infection. Knockdown of CEACAM6 with small interfering RNA significantly increased adenovirus replication and antitumor efficacy of oncolytic adenovirus in a mouse xenograft tumor model. Wang et al. (2009) concluded that CEACAM6 is a tumor-associated gene that affects the ability of cancer cells to be infected with adenovirus.

Mouse neutrophils do not bind the human-restricted pathogen Neisseria gonorrhoeae. Sarantis and Gray-Owen (2012) showed that introducing any of the gonorrheal Opa-binding human neutrophil CEACAMs into a murine neutrophil cell line allowed binding and entry of Neisseria. CEACAM1 and CEACAM6 both bound and allowed entry of the bacterium, but they mediated little neutrophil activation. In contrast, uptake via CEACAM3 (609142) induced an oxidative burst and intracellular granule release comparable to that seen during human neutrophil infection. Coexpression of CEACAM3 with either CEACAM1 or CEACAM6 potentiated CEACAM3-dependent responses. Sarantis and Gray-Owen (2012) concluded that, although CEACAMs have different functions in neutrophils, they cooperate during gonorrheal infection. Their findings implicated CEACAM3 in the neutrophil innate response to neisserial infection.

https://www.omim.org/entry/163980?search=CEACAM6&highlight=ceacam6

Step 1: Selection of Candidate gene

CEACAM6 was selected on the basis of its membership to a module associated with neutrophil activation that is part of the fixed "BloodGen3" Blood Transcriptome repertoire (= Module M10.4)

Step 1: Candidate Gene Selection

Altman, Rinchai et al.

Nat Comms.

2021

BloodGen3 Module M10.4

Gene Composition

BPI

https://www.genecards.org/cgi-bin/carddisp.pl?gene=BPI

CEACAM6

https://www.genecards.org/cgi-bin/carddisp.pl?gene=CEACAM6

CEACAM8

https://www.genecards.org/cgi-bin/carddisp.pl?gene=CEACAM8

DEFA1

https://www.genecards.org/cgi-bin/carddisp.pl?gene=DEFA1

DEFA3

https://www.genecards.org/cgi-bin/carddisp.pl?gene=DEFA3

DEFA4

https://www.genecards.org/cgi-bin/carddisp.pl?gene=DEFA4

ELANE

https://www.genecards.org/cgi-bin/carddisp.pl?gene=ELANE

LTF

https://www.genecards.org/cgi-bin/carddisp.pl?gene=LTF

MPO

CTSG

https://www.genecards.org/cgi-bin/carddisp.pl?gene=CTSG

OLFM4

https://www.genecards.org/cgi-bin/carddisp.pl?gene=OLFM4

Functional Profiling

https://ayllonbe.github.io/modulesV3/modules_results_html/M10.4.json.html

Gsan

Innate Response in Mucosa

Neutrophil Degranulation

Defense Response to Fungal Pathogens

Proteolysis

Defense Response to gram negative bacteria

Lipopolysaccharide Signaling

CEACAM6

CEACAM8

ELANE

MPO

OLFM4

DEFA1

DEFA3

BPI

CTSG

DEFA4

DEFA1B

LTF

CEACAM6

CEACAM8

ELANE

MPO

OLFM4

DEFA1

DEFA3

BPI

CTSG

DEFA4

DEFA1B

LTF

CEACAM6_degranulation

CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("granules" OR "degranulation" [tiab])

Query

Query Link

https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22granules%22+OR+%22degranulation%22+%5Btiab%5D%29&show_snippets=off&sort=pubdate&size=200

Results

9 Articles

(Feb 08, 2022)

https://pubmed.ncbi.nlm.nih.gov/?term=34639156+18056392+8890209&show_snippets=off&sort=pubdate&size=200

Results Link

https://pubmed.ncbi.nlm.nih.gov/8543346/

Highlights

Neutrophil activation

IPA

Acumenta Biotech

Literature Lab

http://www.acumenta.com/literature-lab-1

Red = strong association

LitLab

Orange = moderate association

TF Motifs

No result found for this module

No result found for this module

RcisTarget

Transcription factor binding

Motif Enrichment

https://motoufiq.github.io/DC_Gen3_Module_Analysis/

RcisTarget Reference Web page

https://pubmed.ncbi.nlm.nih.gov/28991892/

https://www.bioconductor.org/packages/release/bioc/html/RcisTarget.html

Transcriptional Profiles

https://drinchai.shinyapps.io/BloodGen3Module/

Learn more about creating dynamic, engaging presentations with Prezi